BKM Wealth Management LLC Grows Holdings in Johnson & Johnson (NYSE:JNJ)

BKM Wealth Management LLC grew its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 14,524 shares of the company’s stock after buying an additional 212 shares during the quarter. BKM Wealth Management LLC’s holdings in Johnson & Johnson were worth $2,100,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in JNJ. Kestra Investment Management LLC raised its position in shares of Johnson & Johnson by 16.7% during the 4th quarter. Kestra Investment Management LLC now owns 24,422 shares of the company’s stock valued at $3,532,000 after acquiring an additional 3,499 shares in the last quarter. Atria Wealth Solutions Inc. raised its position in shares of Johnson & Johnson by 1.7% during the 4th quarter. Atria Wealth Solutions Inc. now owns 162,782 shares of the company’s stock valued at $23,542,000 after acquiring an additional 2,784 shares in the last quarter. Kornitzer Capital Management Inc. KS raised its position in shares of Johnson & Johnson by 1.5% during the 4th quarter. Kornitzer Capital Management Inc. KS now owns 349,105 shares of the company’s stock valued at $50,488,000 after acquiring an additional 5,251 shares in the last quarter. Mraz Amerine & Associates Inc. raised its position in shares of Johnson & Johnson by 38.9% during the 4th quarter. Mraz Amerine & Associates Inc. now owns 24,118 shares of the company’s stock valued at $3,488,000 after acquiring an additional 6,760 shares in the last quarter. Finally, Venturi Wealth Management LLC raised its position in shares of Johnson & Johnson by 61.7% during the 4th quarter. Venturi Wealth Management LLC now owns 19,662 shares of the company’s stock valued at $2,843,000 after acquiring an additional 7,502 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Johnson & Johnson

In related news, Director Mark A. Weinberger purchased 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the transaction, the director now directly owns 1,000 shares of the company’s stock, valued at $147,220. This trade represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Timothy Schmid sold 403 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the transaction, the executive vice president now owns 15,098 shares of the company’s stock, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Leerink Partners dropped their price target on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research report on Thursday, January 23rd. Wolfe Research initiated coverage on Johnson & Johnson in a research report on Friday, November 15th. They issued an “outperform” rating and a $190.00 target price on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a research report on Wednesday. Bank of America dropped their target price on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating on the stock in a research report on Thursday, January 23rd. Finally, Wells Fargo & Company dropped their target price on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 23rd. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $170.67.

Johnson & Johnson Price Performance

Shares of JNJ opened at $162.35 on Friday. The firm has a market capitalization of $390.87 billion, a price-to-earnings ratio of 24.41, a price-to-earnings-growth ratio of 2.53 and a beta of 0.52. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. Johnson & Johnson has a one year low of $140.68 and a one year high of $168.85. The stock’s fifty day moving average is $148.93 and its 200-day moving average is $155.90.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. During the same quarter last year, the business posted $2.29 earnings per share. The company’s quarterly revenue was up 5.3% on a year-over-year basis. Equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.06%. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.